Cell Therapeutics regains rights to cancer compounds from Novartis

Cell Therapeutics (CTIC) will reacquire the rights to Pixuvri and Opaxio from Novartis (NVS) on the condition that NVS receive "certain potential payments ... based on sales [and] any sublicens[ing]."

"Regaining full rights to these two anti-cancer agents ... provides us with the flexibility to manage these assets within the context of our overall product portfolio strategy," CTIC CEO James Bianco says. (PR)

Recently: CTiC rallies on NICE nod for Pixuvri

CTIC +12% premarket

From other sites
Comments (2)
  • Jibo
    , contributor
    Comments (149) | Send Message
    Based on just its present condition this stock should be between $7 and $9 today.
    21 Jan 2014, 11:49 AM Reply Like
  • Jibo
    , contributor
    Comments (149) | Send Message
    Bears try to use an opportunity (slow down in Asia) today, they started shorting this stock at premarket for no particular reason. The question is why it is allowed to set sales price 10% less than the current market price on a premarket trade when there is no reason for it??? I guess we need new regulations on short sales as Europeans have already adopted more than a year ago.
    27 Jan 2014, 10:03 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs